New Cervical Lymphatic-Venous Bypass Surgery for Early-Stage Alzheimer’s Studied in Spain
The Hospital Germans Trias i Pujol in Badalona, Spain, has launched a Phase I clinical trial—the first of its kind in Europe—to test cervical lymphatico-venous anastomosis as a potential treatment for early-stage Alzheimer’s disease. Known as the ALCEA study, the trial aims to evaluate the safety and viability of this extracranial micro-surgical procedure, which seeks to improve brain drainage by connecting lymphatic vessels to veins in the neck.
How the Surgical Drainage Works
The procedure is designed to bypass traditional, less efficient drainage pathways to help clear neurotoxic proteins, such as beta-amyloid and tau, that accumulate in the brains of Alzheimer’s patients. Dr. Carmen Higueras, head of the Plastic and Reconstructive Surgery Service at the Hospital Germans Trias, states that the micro-surgery connects small-caliber veins with lymphatic vessels to redirect fluid flow. This process is intended to descongest the brain and facilitate the removal of waste products associated with cognitive decline.
The surgery is minimally invasive, performed using a surgical microscope and small-diameter sutures. According to the hospital, patients typically undergo the procedure as ambulatory surgery or require only short hospital stays.
The surgical approach of cervical lymphatico-venous anastomosis was first performed in humans in China. While several international trials are currently underway, including 21 in China, one in Seoul, two in Singapore, and one in Taiwan, the ALCEA study represents the first implementation of this specific research protocol in Europe.
Clinical Observations and Cautions
The study involves the sequential inclusion of 10 patients with early-stage Alzheimer’s who will be monitored for at least 12 months. To date, surgeons have operated on two patients. Dr. Pau Pastor, a neurologist at the hospital, reports that one of these patients has shown some functional improvement, though he emphasizes that the trial remains in a very early stage where the primary goal is ensuring patient safety rather than confirming clinical efficacy.
Dr. Guillermo García Ribas, a neurologist at the Hospital Universitario Ramón y Cajal and member of the CEAFA expert panel, offers a cautious perspective. While he notes the procedure is not dangerous due to its superficial nature, he stresses that long-term data is essential. According to Dr. García Ribas, the scientific community must still prove that the surgery effectively maintains open channels over time and that increased protein clearance translates into tangible improvements for patients.
The significance of this trial lies in its focus on the brain’s waste-clearance systems, a shift in Alzheimer’s research. While the surgical drainage is a novel approach, it is currently being evaluated alongside established non-pharmacological interventions, such as physical activity and dietary adjustments, which are also thought to influence lymphatic drainage. The clinical challenge remains determining whether this surgical “reset” of drainage pathways can meaningfully alter the long-term progression of a disease that involves the entire brain.
What May Happen Next
If the ALCEA study successfully demonstrates safety and sustained patency of the lymphatic-venous connections, it could provide a foundation for further research into brain clearance mechanisms. Analysts and clinicians suggest that this could eventually lead to the development of less invasive therapies. These may include therapeutic apheresis—a process similar to dialysis for blood and fluid cleaning—or pharmacological treatments designed to reduce perivascular inflammation and activate internal drainage systems.
Frequently Asked Questions
What is the primary goal of the ALCEA study?
The study aims to determine the safety, viability, and potential effects of cervical lymphatico-venous anastomosis in patients with early-stage Alzheimer’s disease.
Is this surgery considered a cure for Alzheimer’s?
No. Both Dr. Higueras and Dr. Pastor emphasize that the medical community is currently far from a cure, noting that there is currently no tool available to stop the progression of the disease.
Why is the surgery performed in the neck?
The neck provides access to superficial areas where surgeons can connect the lymphatic system to the venous system. This bypasses the need for intracranial access while creating a faster drainage route for cerebrospinal fluid and metabolic waste.
How might these findings influence the broader approach to managing neurodegenerative conditions in the future?